Democrats Press Trump Administration Over 79-Year-Old's Access to Eli Lilly Obesity Drug
Updated
Updated · STAT · Jun 25
Democrats Press Trump Administration Over 79-Year-Old's Access to Eli Lilly Obesity Drug
3 articles · Updated · STAT · Jun 25
Summary
Democratic lawmakers are demanding details on an unnamed 79-year-old patient who received April access to Eli Lilly’s experimental obesity drug retatrutide, asking whether the recipient was President Donald Trump or another prominent figure.
STAT reported Eli Lilly and the FDA provided the drug through the agency’s compassionate-use pathway, which allows experimental treatments for patients with serious, immediately life-threatening conditions.
The patient was described as having refractory obesity, obstructive sleep apnea and pulmonary hypertension, conditions cited in the special-access case now drawing political scrutiny.
The questions center on whether the Trump administration gave unusual access to a high-profile patient, widening attention on how compassionate-use decisions are handled.